EUROPE: ABPI takes issue with NICE recommendations.
The Association of the British Pharmaceutical Industry (ABPI) is taking issue with the process by which the National Institute for Health and Clinical Excellence (NICE) reaches its recommendations. NICE is, inter alia, responsible for evaluating new and existing treatments for use within the UK's National Health Service.
NICE state that they base their recommendations on both clinical evidence (how well the medicine or treatment works) and economic evidence (how well the medicine or treatment works in relation to how much it costs the NHS). The ABPI believes that NICE is applying arbitrary thresholds of 'cost-effectiveness' and, where there is uncertainty in the process, patients are often denied the benefit of doubt.
No comments:
Post a Comment